Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-02-27
2008-03-04
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S399000
Reexamination Certificate
active
07338934
ABSTRACT:
Disclosed is a human Fibroblast growth factor-14 polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for promoting wound healing for example as a result of burns and ulcers, to prevent neuronal damage due to associated with stroke and promote neuronal growth, and to prevent skin aging and hair loss, to stimulate angiogenesis, mesodermal induction in early embryos and limb regeneration. Antagonists against such polypeptides and their use as a therapeutic to prevent abnormal cellular proliferation, hyper-vascular diseases and epithelial lens cell proliferation are also disclosed. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.
REFERENCES:
patent: 5773252 (1998-06-01), Green et al.
patent: WO-96/39506 (1996-12-01), None
patent: WO-97/35007 (1997-09-01), None
patent: WO-99/27100 (1999-06-01), None
Basilico, et al.,Advances in Cancer Research, 59:115-165 (1992).
EMBL Database, Accession No. T27215 (Dec. 31, 1994).
Galzie, et al., “Fibroblast growth factors and their receptor,”Biochem. CII Biol., 75(669-685 (1997).
Genbank Accession No. Z44732 (Nov. 14, 1994).
Genbank Accession No. H15590 (Jun. 27, 1995).
Genbank Accession No. T27215 (Sep. 5, 1995).
Genbank Accession No. HSU66199 (Nov. 15, 1996).
GENESEQ, T86313, Mar. 27, 1998, disclosing a nucleic acid sequence presented in PCT publication No. WO97/35007A1.
Gospodarowicz, D.,Cell Biology Reviews, 25(4):307-314 (1991).
Klagsbrun, M., “The fibroblast growth factor family: structural and biological properties,” Progress in Growth Factor Research, 1:207-235, issued 1989.
Olsen, et al., “Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs,”J Bio Chem., 278(36):34226-34236 (Sep. 5, 2003).
Powers, et al., “Fibroblast growth factors, their receptors and signaling”,Endocrine-Related Cancer, 7:165-167 (2000).
Schoorlemmer, et al., “Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase,”J Bio Chem., 277(51):49111-49119 (Dec. 20, 2002).
Smallwood, et al.,Proc. Natl. Acad. Sci.,USA, 93(9850-9857 (1996).
Szebenyi, et al., “Fibroblast growth factors as multifunctional signaling factors,”International Review of Cytology, 185:45-106 (1999).
Terada, et al., Origins of Human Cancer: A Comprehensive Review, 675-683 (1991).
Dillon Patrick J.
Greene John M.
Allen Marianne P.
Human Genome Sciences Inc.
LandOfFree
Fibroblast growth factor-14 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibroblast growth factor-14, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibroblast growth factor-14 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3980021